title: Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
abstract: We examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic concentrations after continuous transdermal absorption in squirrel monkeys rendered parkinsonian by MPTP. Direct subcutaneous administration of (+)-PHNO in the dose range of 2.5 to 20 micrograms/kg restored locomotor activity to levels seen in normal monkeys for approximately 1 hour. Application of transdermal patches capable of delivering, into an infinite sink, an estimated 2.6 micrograms/cm2/h of (+)-PHNO over a skin surface area of 4.78 to 19.12 cm2 also restored locomotor activity to the normal range during a 24-hour period. We suggest the use of transdermal application of PHNO as a novel drug delivery system for the improved management of Parkinson's disease.
authors: Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, England.
authors: N M
authors: NM
authors: Rupniak
authors: S J
authors: SJ
authors: Tye
authors: C A
authors: CA
authors: Jennings
authors: A E
authors: AE
authors: Loper
authors: J V
authors: JV
authors: Bondi
authors: M
authors: M
authors: Hichens
authors: E
authors: E
authors: Hand
authors: S D
authors: SD
authors: Iversen
authors: S M
authors: SM
authors: Stahl
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000279:Administration, Cutaneous; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000097:blood; D001522:Behavior, Animal / Q000187:drug effects; D008297:Male; D010078:Oxazines / Q000008:administration & dosage* / Q000097:blood; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D011725:Pyridines; D012453:Saimiri
chemical_list: D000978:Antiparkinson Agents; D010078:Oxazines; D011725:Pyridines; C042631:naxagolide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine